SOURCE: Bio Launch Strategies, LLC

March 24, 2005 10:00 ET

Bio Launch Strategies Announces Distribution Agreement With MedAssets Supply Chain Systems

Bio Launch Strategies, LLC Today Announces Agreement With MedAssets Supply Chain Systems to Provide Bio-Guard Bacterial Disinfectant™ to the MedAssets Membership

Bio-Guard Bacterial Disinfectant™ Is an EPA-Approved Odorless, Tasteless, and Completely Non-Toxic Disinfectant Product That Represents a Revolutionary New Patented Technology in the Fight Against Hospital Acquired Infections

ST. PETERS, MO -- (MARKET WIRE) -- March 24, 2005 -- Bio Launch Strategies, LLC, a Biopharmaceutical Consulting and Marketing Company, announced today they have entered into an agreement with MedAssets Supply Chain Systems to provide Bio-Guard Bacterial Disinfectant™ to the MedAssets membership. MedAssets, through its supply chain subsidiary MedAssets Supply Chain Systems, operates the fastest growing group purchasing organization and supply chain services company in the U.S. and builds customized solutions encompassing procurement of common medical supplies, pharmaceuticals, physician preference supplies, and capital equipment. MedAssets serves more than 22,000 healthcare providers nationwide through its revenue cycle and supply chain operations.

Bio-Guard Bacterial Disinfectant™ is a unique antimicrobial disinfectant approved by the EPA for use as a full-range disinfectant against some of the deadliest pathogens known to man. Bio-Guard Bacterial Disinfectant™ has been EPA approved as a broad spectrum but non-toxic surface disinfectant for use in hospitals, medical environments, residential homes and commercial buildings. Bio-Guard Bacterial Disinfectant™ has been approved for use against Gram Positive bacteria such as Staphylococcus aureus (the leading cause of bacterial deaths in U.S. hospitals), Gram Negative bacteria such as Salmonella choleraesuis (food poisoning), and Nosocomial or hospital induced pathogens like Pseudomonas aeruginosa (burns and cuts).

"We believe that this agreement is a significant step in addressing the issue of hospital borne infections," states Dean Erhardt, President of Bio Launch Strategies. "This product has been proven extremely effective against staph aureus (presently considered the most deadly bacteria in U.S. hospitals) and a host of other deadly pathogens. "Bio-Guard Bacterial Disinfectant™ utilizes a patented technology that makes it unique compared to like products." Mr. Erhardt states, "While the product is extremely deadly to bacteria, it has a unique advantage over currently used products in the fact that it has no smell, no color, and is completely non-toxic based on recommended usage. It can be sprayed in and around areas where patients are housed without endangering lives with toxic chemical exposure. The product is so safe that if a person were to accidentally consume it, that individual would not be harmed."

Bio-Guard Bacterial Disinfectant™ was developed by American Biotech Labs in Alpine, Utah, and has been proven effective in thousands of scientific tests in major university and clinical facilities worldwide. Bio-Guard's patented technology has been listed in the Senate Registry as a product that can and will help the country in times of trouble.

Facts about Hospital Acquired Infections:

1. Hospital infections claim approximately 90,000 lives per year and
   are reported to be the sixth leading cause of death in the U.S.
2. About one out of twenty persons or approximately 2 million patients
   per year contract infections unrelated to their original condition
   while in the hospital.
3. The Centers for Disease Control and Prevention estimates that
   hospital-acquired infections add $5 billion annually to direct
   patient care costs.
Bio Launch Strategies, LLC is a Biopharmaceutical Consulting and Marketing company specializing in the commercialization and marketing of unique biotech, pharmaceutical and over-the-counter products.

To order Bio-Guard Bacterial Disinfectant™, call 636-699-4110.

Contact Information